- Conditions
- Urinary Bladder Neoplasms
- Interventions
- E7766
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 154
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- PF-06801591, Bacillus Calmette-Guerin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 24 more
- Conditions
- Stage IV Resectable Melanoma
- Interventions
- Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy
- Procedure · Other
- Lead sponsor
- Saint John's Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 15
- States / cities
- Sacramento, California • Santa Monica, California • Chicago, Illinois + 11 more
- Conditions
- Non-Muscle Invasive Bladder Carcinoma
- Interventions
- Accelerometry, BCG Solution, Electronic Health Record Review, Patient Discharge, Survey Administration
- Procedure · Biological · Other + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Bladder Cancer, Urinary Bladder Neoplasms
- Interventions
- MK-3120
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Bakersfield, California • New Brunswick, New Jersey • Myrtle Beach, South Carolina + 1 more
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Erdafitinib Intravesical Delivery System
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more
- Conditions
- Bladder Carcinoma in Situ (CIS)
- Interventions
- ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
- Drug
- Lead sponsor
- Fidia Farmaceutici s.p.a.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • New Orleans, Louisiana • Baltimore, Maryland + 3 more
- Conditions
- Prostate Carcinoma
- Interventions
- Computer-Assisted Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer
- Interventions
- BCG vaccine, prostate cancer vaccine ONY-P1, placebo
- Biological · Other
- Lead sponsor
- Kael-GemVax Co., Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Bladder Cancer
- Interventions
- Bacille Calmette-Guerrin (BCG), Lenalidomide
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urinary Bladder Neoplasm, Urinary Bladder Cancer, Urogenital Neoplasms, Urologic Neoplasms, Urologic Cancer, Malignant Tumor of the Urinary Bladder, Cancer of the Bladder
- Interventions
- NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care, NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
- Drug · Other
- Lead sponsor
- NanOlogy, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Baltimore, Maryland • New York, New York + 2 more
- Conditions
- Colorectal Cancer
- Interventions
- BCG vaccine, autologous tumor cell vaccine, fluorouracil, leucovorin calcium, adjuvant therapy
- Biological · Drug · Procedure
- Lead sponsor
- Intracel
- Industry
- Eligibility
- 21 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 2
- States / cities
- Allentown, Pennsylvania • Fairfax, Virginia
- Conditions
- Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
- Interventions
- BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- BCG (50mg/instillation) + N-803 (400 μg/instillation), BCG (50mg/instillation)
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2039
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
- Interventions
- FK-PC101, Standard of Care (SOC)
- Biological
- Lead sponsor
- Cellvax Therapeutics Inc
- Industry
- Eligibility
- Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina
- Conditions
- Tuberculosis
- Interventions
- BCG strain Connaught, BCG strain Danish, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
- Interventions
- Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
- Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells
- Interventions
- MK-3475 and BCG
- Drug
- Lead sponsor
- Shaheen Alanee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
- Interventions
- CG0070 Adenovirus Vector, Control Arm: Quadruple Choice
- Biological · Other
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 4 more
- Conditions
- Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
- Interventions
- BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 174
- States / cities
- Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more
- Conditions
- Bladder Cancer
- Interventions
- BCG strain of Mycobacterium bovis
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
- Interventions
- inodiftagene vixteplasmid
- Drug
- Lead sponsor
- Anchiano Therapeutics Israel Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more
- Conditions
- Tuberculosis, Diabetes Mellitus
- Interventions
- BCG
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- Gemcitabine, Docetaxel, Bacillus Calmette Guerin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 229
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more